2013

article thumbnail

Is there common ground for engagement between doctors and pharma?

pharmaphorum

Join a cross-stakeholder panel, including the CEO of Doctors.net.uk, a pharmaceutical industry digital engagement expert and two doctors, to understand areas of mutual interest for doctors engaging with pharma online and the specific types of information and dialogue they are seeking.

Doctor 52
article thumbnail

Patient Recruitment: Taking the Low Road

Placebo Control

The Wall Street Journal has an interesting article on the use of “Big Data” to identify and solicit potential clinical trial participants. The premise is that large consumer data aggregators like Experian can target patients with certain diseases through correlations with non-health behavior. Examples given include “a preference for jazz” being associated with arthritis and “shopping online for clothes” being an indicator of obesity.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Half of All Trials Unpublished*

Placebo Control

(*For certain possibly nonstandard uses of the word "unpublished") This is an odd little study. Instead of looking at registered trials and following them through to publication, this study starts with a random sample of phase 3 and 4 drug trials that already had results posted on ClinicalTrials.gov - so in one, very obvious sense, none of the trials in this study went unpublished.

Trials 40
article thumbnail

Brave New Biopharm Blogging

Placebo Control

Although a few articles on this site are older, I really only began blogging in earnest about 15 months ago. However, I suppose that's long enough that I can count myself as at least somewhat established, and take a moment to welcome and encourage some interesting newcomers to the scene. Bloggers in dank basements their natural habitat. There are 3 relative newcomers that I've found really interesting, all with very different perspectives on drug development and clinical research: Pharmagellan T

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Questionable Enrollment Math(s) - the Authors Respond

Placebo Control

The authors of the study I blogged about on Monday were kind enough to post a lengthy comment, responding in part to some of the issues I raised. I thought their response was interesting, and so reprint it in its entirety below, interjecting my own reactions as well. There were a number of points you made in your blog and the title of questionable maths was what caught our eye and so we reply on facts and provide context.

Trials 40
article thumbnail

Questionable Enrollment Math at the UK's NIHR

Placebo Control

There has been considerable noise coming out of the UK lately about successes in clinical trial enrollment. First, a couple months ago came the rather dramatic announcement that clinical trial participation in the UK had " tripled over the last 6 years ". That announcement, by the chief executive of the Sweet creature of bombast: is Sir John writing press releases for the NIHR?

More Trending

article thumbnail

Counterfeit Drugs in Clinical Trials?

Placebo Control

This morning I ran across a bit of a coffee-spitter : in the middle of an otherwise opaquely underinformative press release fromTranscelerate Biopharma about the launch of their Counterfeits flooding the market? Really? "Comparator Network" - which will perhaps streamline member companies' ability to obtain drugs from each other for clinical trials using active comparator arms - the CEO of the consortium, Dalvir Gill, drops a rather remarkable quote: "Locating and accessing these comparators at

article thumbnail

Brazen Scofflaws? Are Pharma Companies Really Completely Ignoring FDAAA?

Placebo Control

Results reporting requirements are pretty clear. Maybe critics should re-check their methods? Ben Goldacre has rather famously described the clinical trial reporting requirements in the Food and Drug Administration Amendments Act of 2007 as a “ fake fix ” that was being thoroughly “ignored” by the pharmaceutical industry. Pharma: breaking the law in broad daylight?

article thumbnail

Preview of Enrollment Analytics: Moving Beyond the Funnel (Shameless DIA Self-Promotion, Part 2)

Placebo Control

Are we looking at our enrollment data in the right way? I will be chairing a session on Tuesday on this topic, joined by a couple of great presenters (Diana Chung from Gilead and Gretchen Goller from PRA). Here's a short preview of the session: Hope to see you there. It should be a great discussion. Session Details: June 25, 1:45PM - 3:15PM Session Number: 241 Room Number: 205B 1.

article thumbnail

Pediatric Trial Enrollment (Shameless DIA Self-Promotion, Part 1)

Placebo Control

[ Fair Warning: I have generally tried to keep this blog separate from my corporate existence, but am making an exception for two quick posts about the upcoming DIA 2013 Annual Meeting.] Improving Enrollment in Pediatric Clinical Trials Logistically, ethically, and emotionally, involving children in medical research is greatly different from the same research in adults.

Trials 40
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Can FDA's New Transparency Survive Avandia?

Placebo Control

PDUFA V commitments signal a strong commitment to tolerance of open debate in the face of uncertainty. I can admit to a rather powerful lack of enthusiasm when reading about interpersonal squabbles. It’s even worse in the scientific world: when I read about debates getting mired in personal attacks I tend to simply stop reading and move on to something else.

Trials 40
article thumbnail

Clinical Trial Enrollment, ASCO 2013 Edition

Placebo Control

Even by the already-painfully-embarrassingly-low standards of clinical trial enrollment in general, patient enrollment in cancer clinical trials is slow. Horribly slow. In many cancer trials, randomizing one patient every three or four months isn't bad at all – in fact, it's par for the course. The most commonly-cited number is that only 3% of cancer patients participate in a trial – and although exact details of how that number is measured are remarkably difficult to pin down, it certainly can'